Fig. 9

Targeted NO release in the myocardium prevented heart dysfunction. a–c The expression level of clinical markers in the serum of different groups (n = 8). d–i Echocardiographic assessment of LV functions (n = 8). Data were presented as mean ± SD, *P < 0.05; **P < 0.01. LVEDD, left ventricular internal diameter at the end of diastole; LVESD, left ventricular internal diameter at the end of systole; LV VOL d, left ventricular volumes at the end diastole; LV VOL s, left ventricular volumes at the end systole; EF, ejection fraction; FS, fraction shorting. j Blood pressure measurements of the animals (n = 8). Data were presented as mean ± SD, *P < 0.05; **P < 0.01. SBP, systolic blood pressure; DBP, diastolic blood pressure. k Representative M-mode echocardiograms presented in the parasternal short-axis view (at the level of papillary muscle) for FS and EF measurements following different treatments. l Representative morphological analysis by H&E staining (scale bar = 100 μm)